Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001140361-24-049871·BioXcel Therapeutics, Inc.
Schedule 13G ownership disclosure
BIOXCEL THERAPEUTICS INC
Common Stock, par value $0.001 per share · CUSIP: 09075P105
Event date: 2024-11-25
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Oaktree Fund Advisors, LLC
Shares: 822,944 · Class: 1.6%
- OAKTREE CAPITAL MANAGEMENT LP
Shares: 1,901,131 · Class: 3.6%
- Oaktree Capital Group Holdings GP, LLC
Shares: 2,724,075 · Class: 5.2%
- Oaktree Capital Holdings, LLC
Shares: 2,724,075 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001140361-24-049871
- Form type
- SCHEDULE 13G
- Filer
- BioXcel Therapeutics, Inc.
- CIK
- CIK 1720893
- Filed
- Dec 18, 2024
- Reporting period
- Nov 25, 2024
- Description
- Schedule 13G beneficial ownership